HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Milan Zdravkovic Selected Research

liraglutide

8/2012Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.
3/2011GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide.
12/2010Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide.
4/2010Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.
7/2009Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).
2/2009Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
1/2009Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
6/2007Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.
6/2006An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Milan Zdravkovic Research Topics

Disease

4Type 2 Diabetes Mellitus (MODY)
08/2012 - 02/2009
3Hypoglycemia (Reactive Hypoglycemia)
07/2009 - 06/2007
3Body Weight (Weight, Body)
01/2009 - 06/2006
2Weight Loss (Weight Reduction)
08/2012 - 07/2009
2Nausea
08/2012 - 01/2009
2Neoplasms (Cancer)
03/2011 - 04/2010
2Weight Gain
07/2009 - 02/2009
1Thyroid Neoplasms (Thyroid Cancer)
03/2011
1Hyperplasia
04/2010
1Vomiting
02/2009
1Thrombosis (Thrombus)
06/2002
1Coronary Stenosis (Coronary Artery Stenosis)
06/2002

Drug/Important Bio-Agent (IBA)

9liraglutideFDA Link
08/2012 - 06/2006
3glimepiride (Amarel)FDA LinkGeneric
08/2012 - 01/2009
2Glucose (Dextrose)FDA LinkGeneric
08/2012 - 02/2009
2Glucagon-Like Peptide 1 (GLP 1)IBA
03/2011 - 06/2007
2glucagon-like peptide receptor (receptor, glucagon-like peptide)IBA
03/2011 - 04/2010
2Calcitonin (Calcitonin, Eel)FDA LinkGeneric
03/2011 - 04/2010
1Gastrointestinal Hormones (Hormones, Gastrointestinal)IBA
08/2012
1AntralIBA
08/2012
1Insulin (Novolin)FDA Link
02/2009
1Metformin (Glucophage)FDA LinkGeneric
01/2009
1FibrinIBA
06/2002